Methotrexaat Focus

Methotrexate, the active ingredient in Methotrexaat Focus, is an antimetabolite (folate antagonist) presented as a subcutaneous formulation for subcutaneous use. It is employed in the treatment of certain cancers, autoimmune disorders and other serious medical conditions in adult patients. It is indicated for both oncologic and rheumatologic indications, offering a versatile therapeutic option.

GNH USA supplies Methotrexaat Focus as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution.

Methotrexate is used across several disease families, primarily targeting rapidly dividing cells and immune‑mediated pathways. - Rheumatoid arthritis: reduces joint inflammation and disease activity, improving functional ability. - Psoriasis: slows skin cell proliferation, leading to clearer lesions. - Acute lymphoblastic leukemia: interferes with malignant cell growth, contributing to remission. - Non‑Hodgkin lymphoma: hampers tumor cell replication, supporting disease control. - Breast cancer: used in combination regimens to inhibit tumor progression. - Ectopic pregnancy: stops trophoblastic growth, facilitating medical management.

Methotrexate may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea and vomiting. - Fatigue or malaise. - Oral mucosal ulceration. - Mild elevation of liver enzymes.

Serious or Rare Side Effects: - Severe bone marrow suppression leading to pancytopenia. - Pulmonary toxicity, including interstitial pneumonitis. - Hepatic fibrosis or cirrhosis with long‑term use.

Methotrexate requires careful monitoring and patient counseling before and during therapy. - Blood monitoring: perform regular complete blood counts to detect myelosuppression. - Liver function: assess hepatic enzymes periodically to identify toxicity. - Renal function: adjust dosing or avoid use in severe renal impairment. - Pregnancy: contraindicated; ensure effective contraception for both sexes. - Breastfeeding: not recommended due to drug excretion in milk. - Store at ambient temperature: keep in original packaging, protect from moisture and direct sunlight.

Methotrexate interacts with several medicines that can alter its safety or efficacy.

Major Interactions (Avoid): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): increase methotrexate toxicity. - Trimethoprim‑sulfamethoxazole: heighten risk of bone marrow suppression. - Live vaccines: may cause severe infection due to immunosuppression.

Moderate Interactions (Monitor Closely): - Azathioprine or other immunosuppressants: additive myelosuppressive effect. - Proton pump inhibitors: may raise methotrexate serum levels. - Penicillins (e.g., ampicillin): can reduce renal clearance of methotrexate.